Brief: Valbiotis Accelerates Its Pipeline Clinical Development

Valbiotis SA

16/04/2020 06:54

April 16 (Reuters) - VALBIOTIS SA  ALVAL.PA :
    * VALBIOTIS ACCELERATES ITS PIPELINE CLINICAL DEVELOPMENT IN
NEW
INDICATIONS: CARDIOVASCULAR AND HEPATIC STEATOSIS RISK REDUCTION
    * LAUNCH OF A PHASE II CLINICAL TRIAL IN Q3 OF 2020
EVALUATING
EFFECT OF TOTUM-070
    * LAUNCH OF A PHASE II CLINICAL TRIAL IN Q4 OF 2020
EVALUATING
EFFECT OF TOTUM-854
    * LAUNCH OF A PHASE II CLINICAL TRIAL IN SECOND HALF OF 2021
EVALUATING EFFECT OF TOTUM-448 IN REDUCING HEPATIC STEATOSIS

Source text for Eikon:  ID:nBwbdj1sTa 
Further company coverage:  ALVAL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))